Humana Inc. (NYSE: HUM) released its financial results for the third quarter of 2025, highlighting a significant decline in income compared to the same period last year. The consolidated income before income taxes for the quarter ending September 30, 2025, stood at $134 million, a sharp decrease from $651 million in the third quarter of 2024. Diluted earnings per share (EPS) reflected a similar trend, falling to $1.62 for 3Q25, down from $3.98 in 3Q24.

Year-to-Date Figures

For the nine months ending September 30, 2025, Humana reported consolidated income before income taxes of $2.566 billion, slightly lower than the $2.583 billion recorded for the same period in 2024. The year-to-date diluted EPS increased marginally to $16.43 from $15.72 year-over-year.

2. Adjusted Financial Metrics

Humana also reported adjusted (non-GAAP) financial results, which provide a more comprehensive view of its operational performance by excluding certain one-time costs and effects from its financial results:

Adjusted income before income taxes: $527 million in 3Q25 compared to $679 million in 3Q24.

Adjusted diluted EPS: $3.24 in 3Q25, down from $4.16 in 3Q24.

Key Adjustments

Humana's adjusted results were influenced by several key factors, including:

Put/call valuation adjustments linked to non-consolidating minority interest investments, which contributed positively with significant adjustments of $97 million in 3Q25 compared to a loss of $59 million in 3Q24.

Value creation initiatives resulted in a robust increase, contributing $267 million in 3Q25 versus $55 million in 3Q24.

The impact of the exit from the employer group commercial medical products business had a negative effect, recording a loss of $62 million in 3Q25.

3. Management Insights

Jim Rechtin, President and CEO of Humana, remarked, “Our strategy of putting the consumer at the heart of everything we do is working, with solid year-to-date performance and strong momentum heading into the Annual Election Period.” He expressed confidence in the company's trajectory and emphasized the value being created for members, patients, and investors alike.

Full-Year Earnings Guidance

Humana also updated its full-year earnings guidance. The company revised its GAAP EPS guidance for the year ending December 31, 2025, to approximately $12.26, down from the previous estimate of $13.77. However, the company affirmed its adjusted EPS guidance of approximately $17.00 for FY 2025.

Important Guidance Details

GAAP EPS: Approximately $12.26 compared to $9.98 in FY 2024.

Adjusted EPS: Projected at approximately $17.00, an increase from $16.21 reported in FY 2024.

4. Revenue Highlights

Humana reported consolidated revenues of $32.649 billion in 3Q25, an increase from $29.397 billion in 3Q24. Year-to-date revenues reached $97.149 billion, up from $88.548 billion the previous year. The growth was primarily driven by the company's insurance segment, which generated $31.189 billion in revenues for 3Q25, compared to $28.370 billion in the same quarter of 2024.

Benefit and Operating Ratios

Benefit Ratio: For 3Q25, the benefit ratio was recorded at 91.1%, indicating a slight increase from 89.9% in 3Q24.

Operating Cost Ratio: The operating cost ratio rose to 12.6% in 3Q25 from 11.5% in 3Q24, reflecting the ongoing investments in value creation initiatives.

5. Upcoming Conference Call

Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time to discuss the financial results and future expectations. This session will provide an opportunity for deeper insights into the company's strategic directions and operational performance.

6. Conclusion

Despite the challenges reflected in the quarterly results, Humana's leadership remains optimistic about the future, focusing on consumer-centric strategies and operational improvements. As the company navigates through this transitional phase, stakeholders will be keenly observing the effects of its strategic initiatives on long-term growth and profitability.

Original press release